Table 4. Triple Differences Estimates for Statistically Significant Difference-in-Differences Estimates.
| Estimate | Cancer evaluation and management visits | Cancer drug administrations | Cancer drug costs, $a | Overall cancer costs, $a | |||||
|---|---|---|---|---|---|---|---|---|---|
| Breast | Colon | Prostate | Lung | Prostate | Breast | Lung | Colon | Prostate | |
| Mean (SD), No. | 0.95 (0.76) | 1.35 (1.12) | 1.20 (1.76) | 5777 (4164) | 3083 (5335) | 2411 (2424) | 3407 (3407) | 2708 (3288) | 2089 (4004) |
| Observations, No. | 11 869 | 8592 | 9045 | 7887 | 6111 | 11 869 | 11 135 | 8592 | 9045 |
| Difference, OCM × postperiod × Medicare status (95% CI)b,c | 0.10 (–0.42 to 0.61) | 0.83 (–0.21 to 1.87) | –0.84 (–2.26 to 0.57) | –3660 (–9431 to 2111) | –1827 (–6250 to 2596) | –30 (–1903 to 1843) | 290 (–2358 to 2939) | 865 (–1824 to 3554) | –2676 (–5735 to 384) |
| P value | .70 | .11 | .23 | .20 | .40 | .97 | .82 | .51 | .08 |
| Change, relative to mean, % | +10.4 | +61.6 | –70.4 | –63.4 | –59.3 | –1.2 | +8.5 | +31.9 | –128 |
Abbrevation: OCM, Oncology Care Model.
a
Costs are in monthly mean terms.
b
Estimates are based on going from 0% to 100% Medicare share.
c
Confidence intervals are calculated using SEs clustered on practice.